Pharmacologic treatments for covid-19 patients

Anakinra vs Standard care/Placebo

On Jan 26th, 2022, we published results of the Interleukin‐1 blocking agents for treating COVID‐19 which included all preprints and published trials published online up to November 5, 2021.


Hospitalized patients

Forest plots
(last update: 2022-01-24)

Summary of findings
(last update: 2022-03-03)

To access all information :

You can print it as a pdf. You can also click on each forest plot with your right mouse button and download.

Permanent URL for this comparison: https://covid-nma.com/living_data/index.php?comparison=223

Back to your research

Trial Funding Comparisons Design Participants Sample size Overall risk
of bias
Highest assessment
Full description
Treatment 1 Treatment 2
IRCT20120703010178N20
Kharazmi AB, Immun Inflamm Dis, 2021
Full text
Commentary
Private

Anakinra

Standard care

RCT Patients with confirmed COVID-19 (moderate-critical) admitted to a single center in Iran. N=30
High
Details

Full description

NCT04330638; EudraCT2020-001500-41
COV-AID
Declercq J, Lancet Respir Med, 2021
Full text
Commentary
Commentary
(21)00405-7
Public/non profit

Anakinra

Tocilizumab

Siltuximab

Anakinra

Anakinra

Tocilizumab

Anakinra + Tocilizumab

Standard care

Standard care

Standard care

Tocilizumab

Siltuximab

Siltuximab

Standard care

RCT Patients with confirmed COVID-19 (moderate-critical) admitted to 16 centers in Belgium. N=342
Some concerns
Details

Full description

NCT02735707
REMAP-CAP
Derde L, medRxiv, 2021
Full text
Commentary
Commentary
Mixed

Tocilizumab

Sarilumab

Anakinra

Standard care

RCT Patients with suspected or confirmed COVID-19 (moderate to critical) admitted to 133 centers in 9 countries N=2253
Some concerns
Details

Full description

NCT04680949; EudraCT 2020-005828-11
SAVE-MORE
Kyriazopoulou E, Nat Med, 2021
Full text
Full text
Commentary
Commentary
Mixed

Anakinra

Placebo

RCT Patients with confirmed COVID-19 (mild-severe) admitted to 37 centers in Greece and Italy N=606
Some concerns
Details

Full description

NCT04341584
CORIMUNO-ANA-1
Mariette X, Lancet Respir Med, 2021
Full text
Commentary
Public/non profit

Anakinra

Standard care

RCT Patients with COVID-19 (moderate) admitted to 16 centers in France. N=116
Some concerns
Details

Full description